Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused bySARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19might be secondary sequelae due to exuberant systemic innate-mediated hyper-inflammation,which may impair neurovascular endothelial function, disrupt blood brain barrier (BBB),activates CNS innate immune signaling pathways, and induces parainfectious autoimmunity,potentially contributing to the CNS manifestations. Although the predominant clinicalmanifestation of SARS-CoV-2 is characterized by dyspnea, unremitting fever and hypoxemicrespiratory failure, neurologic manifestations do occur in most hospitalized SARS-CoV-2patients and include non-specific encephalopathy, psychosis, meningitis/encephalitis,myelitis, cerebrovascular events, Guillain-Barre' syndrome, and cranial or peripheralneuropathies, such as anosmia and ageusia. To date, data about primary CNS involvementdue to neurotropism and direct neuroinvasion are still lacking.
Determination of SARS-CoV-2 presence in central nervous system
Diagnostic Test: Determination of SARS-CoV2 presence in CNS
Brain tissue sampling
Inclusion Criteria:
- Adult patients
- Patients candidate for CNS surgery
- Patients who have been tested for nasopharyngeal swab for SARS-CoV-2
- Patients who have been tested for serology test for anti SARS-CoV-2 immunoglobulinG
(IgG) and immunoglobulinM (IgM) antibodies
- Patients able to sign informed consent
Exclusion Criteria:
- Patients not meeting inclusion criteria
IRCCS San Raffaele Scientific Institute
Milan, Italy
Investigator: Laura Sincinelli
Contact: 003926435568
sincinelli.laura@hsr.it
Laura Sincinelli
00390226435568
sincinelli.laura@hsr.it
Pietro Mortini, MD, Prof., Principal Investigator
IRCCS San Raffaele Scientific Institute